Your browser doesn't support javascript.
loading
Response to letter from Dr Oliviera in relation to our publication: A study in a rat initiation-promotion bladder tumour model demonstrated no promoter/progressor potential of dapagliflozin.
Billger, Martin; Kirk, Jason; Chang, Jane; Bédard, Agathe; Attalla, Bassem; Haile, Solomon; Söderberg, Magnus.
Afiliación
  • Billger M; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. Electronic address: martin.billger@astrazeneca.com.
  • Kirk J; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Chang J; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA, USA.
  • Bédard A; Charles River Laboratories, Montreal, Canada.
  • Attalla B; Charles River Laboratories, Montreal, Canada.
  • Haile S; Charles River Laboratories, Montreal, Canada.
  • Söderberg M; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Regul Toxicol Pharmacol ; 106: 347-348, 2019 08.
Article en En | MEDLINE | ID: mdl-31095971
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria Límite: Animals Idioma: En Revista: Regul Toxicol Pharmacol Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria Límite: Animals Idioma: En Revista: Regul Toxicol Pharmacol Año: 2019 Tipo del documento: Article